Health and Human Services Department (HHS); National Institutes of Health (NIH); National Institute of Allergy and Infectious Diseases (NIAID); the Food and Drug Administration (FDA); the Transformational Medical Technologies (TMT); and Biomedical Advanced Research and Development Authority (BARDA) (F.R. Page 43604) - Workshop
Published in The Washington Daybook
(10.09.2012)
Get full text
Report
Health and Human Services Department (HHS); National Institutes of Health (NIH); National Institute of Allergy and Infectious Diseases (NIAID); the Food and Drug Administration (FDA); the Transformational Medical Technologies (TMT); and Biomedical Advanced Research and Development Authority (BARDA) (F.R. Page 43604) - Workshop
Published in The Washington Daybook
(04.09.2012)
Get full text
Report
Health and Human Services Department (HHS); National Institutes of Health (NIH); National Institute of Allergy and Infectious Diseases (NIAID); the Food and Drug Administration (FDA); the Transformational Medical Technologies (TMT); and Biomedical Advanced Research and Development Authority (BARDA) (F.R. Page 43604) - Workshop
Published in The Washington Daybook
(27.08.2012)
Get full text
Report
Health and Human Services Department (HHS); National Institutes of Health (NIH); National Institute of Allergy and Infectious Diseases (NIAID); the Food and Drug Administration (FDA); the Transformational Medical Technologies (TMT); and Biomedical Advanced Research and Development Authority (BARDA) (F.R. Page 43604) - Workshop
Published in The Washington Daybook
(20.08.2012)
Get full text
Report
Health and Human Services Department (HHS); National Institutes of Health (NIH); National Institute of Allergy and Infectious Diseases (NIAID); the Food and Drug Administration (FDA); the Transformational Medical Technologies (TMT); and Biomedical Advanced Research and Development Authority (BARDA) (F.R. Page 43604) - Workshop
Published in The Washington Daybook
(13.08.2012)
Get full text
Report
Health and Human Services Department (HHS); National Institutes of Health (NIH); National Institute of Allergy and Infectious Diseases (NIAID); the Food and Drug Administration (FDA); the Transformational Medical Technologies (TMT); and Biomedical Advanced Research and Development Authority (BARDA) (F.R. Page 43604) - Workshop
Published in The Washington Daybook
(06.08.2012)
Get full text
Report
Health and Human Services Department (HHS); National Institutes of Health (NIH); National Institute of Allergy and Infectious Diseases (NIAID); the Food and Drug Administration (FDA); the Transformational Medical Technologies (TMT); and Biomedical Advanced Research and Development Authority (BARDA) (F.R. Page 43604) - Workshop
Published in The Washington Daybook
(30.07.2012)
Get full text
Report
Biomedical Advanced Research and Development Authority Based Anthrax Vaccine
Published in PR newswire
(01.10.2013)
Get full text
Newspaper Article
U.S. Biomedical Advanced Research and Development Authority (BARDA) Extends Contract with Protein Sciences Corporation
Published in PR newswire
(17.06.2014)
Get full text
Newspaper Article
Biomedical Advanced Research and Development Authority Based Anthrax Vaccine
Published in PR newswire
(01.05.2012)
Get full text
Newspaper Article
Elusys Awarded $68 Million Contract to Develop Anthim for Intramuscular Pre- and Post-Exposure Prophylaxis of Anthrax Infection: First funding awarded by BARDA (Biomedical Advanced Research & Development Authority) for development of an intramuscular formulation of an anthrax anti-toxin for pre- and post-exposure prophylactic use
Published in PR Newswire
(08.09.2011)
Get full text
Newsletter
Atox Bio Awarded Contract Worth up to $24 Million for the Development of AB103 by the Biomedical Advanced Research and Development Authority (BARDA)
Published in PR newswire
(29.09.2014)
Get full text
Newspaper Article
Visterra Awarded Contract Valued at up to $204.5 Million to Advance the Development of VIS410, its Novel Monoclonal Antibody for the Treatment of Influenza A, by the Biomedical Advanced Research and Development Authority (BARDA)
Published in Business Wire
(05.10.2015)
Get full text
Newspaper Article
Elusys Awarded Additional $40.6 Million Under Existing U.S. Government Contract to Fund Advanced Development of Anthim, a New Treatment for Anthrax: Funding awarded by BARDA (Biomedical Advanced Research & Development Authority); Anthim being developed to treat inhaled anthrax, one of the top bioterrorism threats
Published in PR Newswire
(04.08.2010)
Get full text
Newsletter